Opin vísindi

Can postoperative dexamethasone nanoparticle eye drops replace mitomycin C in trabeculectomy?

Show simple item record

dc.contributor Háskóli Íslands
dc.contributor University of Iceland
dc.contributor.author Johannesson, Gauti
dc.contributor.author Gottfredsdottir, Maria
dc.contributor.author Ásgrimsdóttir, Guðrún Marta
dc.contributor.author Loftsson, Thorsteinn
dc.contributor.author Stefánsson, Einar
dc.date.accessioned 2020-11-24T11:21:56Z
dc.date.available 2020-11-24T11:21:56Z
dc.date.issued 2020-02-17
dc.identifier.citation Jóhannesson, G., Gottfredsdóttir, M.S., Ásgrimsdóttir, G.M., Loftsson, T. and Stefánsson, E. (2020), Can postoperative dexamethasone nanoparticle eye drops replace mitomycin C in trabeculectomy?. Acta Ophthalmologica, 98: 607-612. https://doi.org/10.1111/aos.14370
dc.identifier.issn 1755-375X
dc.identifier.issn 1755-3768 (eISSN)
dc.identifier.uri https://hdl.handle.net/20.500.11815/2233
dc.description Publisher's version (útgefin grein)
dc.description.abstract Purpose: Compare (a) nonmitomycin C (MMC) trabeculectomy and 1.5% dexamethasone nanoparticle (DexNP) eye drops postoperatively with (b) trabeculectomy with MMC and Maxidex® eye drops postoperatively. Methods: Randomized prospective single masked clinical trial with 20 patients with primary open-angle glaucoma undergoing primary trabeculectomy. The study group consisted of 10 patients without MMC intraoperatively and postoperative DexNP eye drops, and the control group consisted of 10 patients treated with MMC intraoperatively and postoperative Maxidex®. The drops were tapered out over 8 weeks. The main outcome measures were as follows: rates of complete success, that is intraocular pressure (IOP) within target pressures at different time-points without IOP-lowering medication, or reoperation. Secondary outcome measures included the following: relative success rate (with IOP-lowering medications), number of glaucoma medications and reoperations. Patients were followed for 36 months. Results: Both groups showed similar postoperative course and IOP reduction. Intraocular pressures (IOPs) in the DexNP group and in the control group were 25.6 and 24.4 mmHg, respectively, at baseline. Intraocular pressures (IOPs) were reduced to 13.2 and 14.5 mmHg at 12 months, 11.7 and 12.6 mmHg at 24 months and 11.7 and 12.1 mmHg at 36 months, respectively. There were no statistically significant differences between the groups in absolute (p = 0.36) or relative (p = 1.0) success rates, number of medications (p = 0.71) or reoperations (p = 1.0) between the groups at any time-point. Conclusions: DexNP eye drops are effective postoperative treatment following trabeculectomy. The potent anti-inflammatory and antifibrotic effect of DexNP may offer an alternative to mitomycin C in glaucoma surgery.
dc.description.sponsorship The authors have received unrestricted grants from the Icelandic Technology Development Fund, Knut and Alice Wallenberg Foundationand and Swedish Society for Medical Research
dc.format.extent 607-612
dc.language.iso en
dc.publisher Wiley
dc.relation.ispartofseries Acta Ophthalmologica;98(6)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Dexamethasone
dc.subject Drug delivery
dc.subject Glaucoma
dc.subject Mitomycin C
dc.subject Nanoparticles
dc.subject Trabeculectomy
dc.subject Augndropar
dc.subject Lyfjagerð
dc.subject Gláka
dc.title Can postoperative dexamethasone nanoparticle eye drops replace mitomycin C in trabeculectomy?
dc.type info:eu-repo/semantics/article
dcterms.license This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
dc.description.version Peer Reviewed
dc.identifier.journal Acta Ophthalmologica
dc.identifier.doi 10.1111/aos.14370
dc.relation.url https://onlinelibrary.wiley.com/doi/full/10.1111/aos.14370
dc.contributor.department Læknadeild (HÍ)
dc.contributor.department Faculty of Medicine (UI)
dc.contributor.department Lyfjafræðideild (HÍ)
dc.contributor.department Faculty of Pharmaceutical Sciences (UI)
dc.contributor.school Heilbrigðisvísindasvið (HÍ)
dc.contributor.school School of Health Sciences (UI)

Files in this item

This item appears in the following Collection(s)

Show simple item record